Susannah Gray
Independent DirectorMs. Susannah Gray, MBA, is an Independent Director of AnaptysBio, Inc. since March 26, 2026. Ms. Gray had been Independent Director of Theravance Biopharma, Inc. since February 26, 2023 until September 23, 2026 and served as its Independent Chairman since November 2024 until September 23, 2026. She is Independent Director of Maravai LifeSciences Holdings, Inc. since November 19, 2020. She serves as an independent Director at Morphic Holding, Inc. since April 2021. she joined as an Independent Director at 4D Molecular Therapeutics, Inc. from July 2020. Ms. Gray served as an Independent Director at Apria, Inc. since May 04, 2021 until March 29, 2022. Ms. Gray serves as an Independent Director at Biosplice Therapeutics, Inc. since April 2021. She serves on Board at Morphic Therapeutic, German Marshall Fund and serves as its Independent Director at BioSplice LLC until 2025. She is a veteran leader in healthcare finance and strategy with experience in capital formation, operational management, healthcare asset monetization, investment research and strategy implementation. Ms. Gray is an Independent Director of Maravai Life Sciences Holdings, Inc. since November 19, 2020. Ms. Gray served as the Chief Financial Officer at Royalty Pharma Management, LLC from January 2005 to December 2018 and served as its Executive Vice President of Finance and Strategy from December 2018 to September 2019. Ms. Gray joined Royalty Pharma in January 2005 in investment banking. She served as Chief Financial Officer and Executive Vice President of RP Management, LLC. She served as a Vice President of Royalty Pharma. From 2002 to 2004, she was a Managing Director and Senior Analyst covering the healthcare sector for CIBC World Market's high yield group. Prior to joining CIBC World Markets, she worked as an Equity Analyst at Merrill Lynch & Co Inc., Research Division. She joined Merrill Lynch in April 1999, served at Chase Securities, Inc. (a predecessor of JP Morgan Securities, Inc.), working in various capacities within the high yield and the structured finance groups. Ms. Gray is a Member of the Board of Directors of corporate and non-profit institutions. Ms. Gray serves on the Board of Directors of Susan G. Komen Foundation, StreetSquash and serves on the Board of Trustees of Wesleyan University. She received a B.A. in Social Studies from Wesleyan University in 1982 and an M.B.A. from Columbia University in 1990.
Positions
- Company NameMaravai LifeSciences Holdings, Inc.Stock CodeMRVIPositionIndependent DirectorColleagues
- RARobert Andrew EckertChairman of the Board
- BBBernd BrustCEO & Director
- RJRajesh J. AsorpotaEVP & Chief Financial Officer
- KAKurt A. OreshackExecutive VP, General Counsel & Secretary
- CDChristine DolanExecutive VP & GM of Cygnus Technologies
- SGSusannah GrayIndependent Director
- JAJohn A. DeFordIndependent Director
- GTGregory Thomas LucierIndependent Director
- Company Name4D Molecular Therapeutics, Inc.Stock CodeFDMTPositionIndependent Director
